Boundless Bio's reverse merger; CARsgen wins first solid tumor approval for CAR-T
Endpoints News reported Boundless Bio's reverse merger and CARsgen's world-first approval of a CAR-T therapy for solid tumors in China.
Boundless Bio
Profile of Boundless Bio created from news harvest. To be enriched by user.
Company Info
Sector:Precision Oncology / ecDNA-directed therapy
Headquarters:San Diego, California, USA
Founded:2019
Website:boundlessbio.com/
Clinical Development Pipeline
Undisclosed
Target: TBDRecent News
Leadership Team
Zachary Hornby
Chief Executive Officer
Careers & Job Openings